A post-marketing surveillance study to evaluate the long-term safety and efficacy of Dimethyl fumarate in Swedish patients with multiple sclerosis

Trial Profile

A post-marketing surveillance study to evaluate the long-term safety and efficacy of Dimethyl fumarate in Swedish patients with multiple sclerosis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMSE-5
  • Sponsors Biogen
  • Most Recent Events

    • 24 Feb 2016 New trial record
    • 10 Oct 2015 Results (n=1077) presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top